Blueprint Medicines Corporation is a precision medicine enterprise, dedicated to inventing therapeutic solutions for genetically characterized cancers and blood disorders. Its operations span both the United States and international markets. Currently, Blueprint is advancing AYVAKIT, prescribed for systemic mastocytosis (SM) and specific gastrointestinal stromal tumors.